https://www.marketscreener.com/quote/stock/AIM-IMMUNOTECH-INC-65218228/news/AIM-ImmunoTech-Inc-Announces-Central-IRB-Approval-of-Phase-2-Study-Protocol-Evaluating-Ampligen-R-43432462/?utm_source=telegram&utm_medium=social&utm_campaign=share